Global investment firm Lanstead is pleased to announce that its Sharing Agreement with AIM quoted, specialist drug discovery and development company, ImmuPharma plc (AIM: IMM) (“ImmuPharma” or the “Company”) has been successfully completed, with ImmuPharma having received over £5 million from Lanstead, £600,000 more than was originally subscribed, through the…

Global investment firm Lanstead has today announced its A$10 million investment in Australian biotechnology firm Neuren Pharmaceuticals Ltd (“Neuren”) (ASX: NEU) ahead of an upcoming Rett syndrome Phase 3 trial. Neuren is developing novel new therapies for brain injuries, neurodevelopmental and neurodegenerative disorders. It currently has a clinical stage molecule,…

Global investment firm Lanstead has today announced a 4.62 million investment in AIM quoted, gold exploration business, KEFI Minerals (AIM: KEFI) as part of a 5.62 million fund raise as KEFI looks to progress its Tulu Kapi project in western Ethiopia. KEFI Minerals has gold exploration and development company with…

Global investment firm Lanstead has today announced its A$4 million investment in SmartTrans Holdings Limited (“SmartTrans”) (ASX: SMA) to fund the expansion of their e-commerce platforms and facilitate the rollout of their SmartPay payments platform in Australia and China. SmartTrans recently announced a Memorandum of Understanding (MOU) with Shanghai Stock…

Global investment firm Lanstead has today announced its £4.4 million investment in AIM quoted, specialist drug discovery and development company, ImmuPharma plc (AIM: IMM) as the business looks to commence its pivotal Phase III clinical trial of Lupuzor™, the Company’s lead programme for the potential breakthrough compound for Lupus, the…